The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of tumor side on clinical outcomes in stage II and III colon cancer with known microsatellite instability status.
 
Katerina Mary Zakka
No Relationships to Disclose
 
Shayla Williamson
No Relationships to Disclose
 
Renjian Jiang
No Relationships to Disclose
 
Olatunji B. Alese
Consulting or Advisory Role - AstraZeneca; Conjupro Biotherapeutics; Exelixis; Ipsen
Research Funding - Acetylon Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Ipsen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Walid Labib Shaib
Honoraria - Ipsen; Ipsen
Consulting or Advisory Role - Blueprint Medicines; Blueprint Medicines; Mylan
Research Funding - ArQule (Inst); Basilea (Inst); Lexicon (Inst); Lilly (Inst)
 
Christina Wu
Consulting or Advisory Role - Array BioPHarma
Research Funding - Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Lycera (Inst); RAPT Therapeutics (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Symphogen (Inst); Vaccinex (Inst)
Travel, Accommodations, Expenses - Array BioPharma
 
Madhusmita Behera
No Relationships to Disclose
 
Bassel F. El-Rayes
Honoraria - Bayer; Lexicon; RTI Health Solutions
Consulting or Advisory Role - Bayer; BTG; Loxo; Merrimack; RTI Health Solutions
Speakers' Bureau - Bristol-Myers Squibb; Lexicon
Research Funding - AstraZeneca/MedImmune (Inst); AVEO (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Cleave Biosciences (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); ICON Clinical Research (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); PPD (Inst); Taiho Pharmaceutical (Inst); Xencor (Inst)
Other Relationship - ERYTECH Pharma; Exelixis
 
Mehmet Akce
Consulting or Advisory Role - Eisai; Ipsen
Research Funding - Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Polaris (Inst); RedHill Biopharma (Inst); Tesaro (Inst); Xencor (Inst)